<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01463813</url>
  </required_header>
  <id_info>
    <org_study_id>FIND</org_study_id>
    <nct_id>NCT01463813</nct_id>
  </id_info>
  <brief_title>Finnish Vitamin D Trial (FIND)</brief_title>
  <acronym>FIND</acronym>
  <official_title>Finnish Vitamin D Trial (FIND)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Eastern Finland</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Academy of Finland</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Juho Vainio Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Finnish Foundation for Cardiovascular Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Finnish Cultural Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Eastern Finland</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Finnish Vitamin D Trial (FIND) is a randomized, double-blind, placebo-controlled, 5-year
      supplementation study of the benefits and risks of vitamin D in the primary prevention of
      cardiovascular (CVD) and cancer among 18000 men 60 years or older and women 65 years or
      older.

      [Edit 25.3.2015: Due to difficulties in recruitment and funding, the study size is
      approximately 2500 subjects, with a 550 subject subgroup with more detailed examinations]

      The participants will be randomized to 3 groups with 6000 in each, with daily supplementation
      of either: 1) 40 µg/day (1600 IU) of vitamin D3, 2) 80 µg/day (3200 IU) of vitamin D3, or 3)
      placebo.

      [Edit 15.3.2015: The 2500 subjects are randomized in 3 groups, approximately 830 subjects per
      group.]

      Compliance, use of non-study drugs or supplements, diet, development of endpoints, and CVD
      and cancer risk factors will be assessed by questionnaires. Blood samples will be collected
      for assessment of effect modification by baseline 25-hydroxyvitamin D, as well as for future
      ancillary studies of genetic/biochemical hypotheses. Event data will be obtained by record
      linkage from the national computerized hospitalization registry.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      More detailed description available upon request.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>September 2012</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">June 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cardiovascular disease</measure>
    <time_frame>5 years</time_frame>
    <description>CVD incidence in VitD arms vs. placebo arm.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cancer</measure>
    <time_frame>5 years</time_frame>
    <description>Cancer incidence in VitD arms vs.placebo arm</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">2495</enrollment>
  <condition>Cardiovascular Diseases</condition>
  <condition>Cancer</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo, no Vitamin D3</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vitamin D3 80</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Vitamin D3 80 micrograms (3200 IU) per day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vitamin D3 40</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Vitamin D3 40 micrograms (1600 IU) per day</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Vitamin D3</intervention_name>
    <description>Vitamin D3 40 micrograms (1600 IU) per day</description>
    <arm_group_label>Vitamin D3 40</arm_group_label>
    <other_name>Cholecalciferol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Vitamin D3</intervention_name>
    <description>Vitamin D3 80 micrograms (3200 IU) per day</description>
    <arm_group_label>Vitamin D3 80</arm_group_label>
    <other_name>Cholecalciferol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Inactive placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men 60 years or older

          -  Women 65 years or older

        Exclusion Criteria:

          -  Cardiovascular disease (including myocardial infarction, stroke, transient ischemic
             attack, angina pectoris, coronary artery bypass grafting, or percutaneous coronary
             intervention).

          -  Cancer (except non-melanoma skin cancer).

          -  Any disease or state that raises a vitamin D related safety concern (such as chronic
             liver, thyroid or kidney disease, hypercalcemia, sarcoidosis or other granulomatous
             diseases such as active chronic tuberculosis or Wegener's granulomatosis).

          -  Use of supplements yielding vitamin D over 20 µg/day or calcium over 1200 mg/day and
             unwillingness to discontinue the use.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tomi-Pekka Tuomainen, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Eastern Finland</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jyrki K Virtanen, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Eastern Finland</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sari Voutilainen, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Eastern Finland</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Eastern Finland, Kuopio Campus</name>
      <address>
        <city>Kuopio</city>
        <state>Savo</state>
        <zip>70211</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Finland</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 13, 2011</study_first_submitted>
  <study_first_submitted_qc>November 1, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 2, 2011</study_first_posted>
  <last_update_submitted>November 7, 2017</last_update_submitted>
  <last_update_submitted_qc>November 7, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 8, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Eastern Finland</investigator_affiliation>
    <investigator_full_name>Tomi-Pekka Tuomainen</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>bone density conservation agents</keyword>
  <keyword>cancer</keyword>
  <keyword>cardiovascular disease</keyword>
  <keyword>cholecalciferol</keyword>
  <keyword>diabetes mellitus, type 2</keyword>
  <keyword>dietary supplements</keyword>
  <keyword>primary prevention</keyword>
  <keyword>vitamin D</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Ergocalciferols</mesh_term>
    <mesh_term>Cholecalciferol</mesh_term>
    <mesh_term>Bone Density Conservation Agents</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

